2026年11月17日 美国东部时间晚上10:30 / CBS新闻
据一名白宫高级官员及其他知情人士透露,白宫已撤回总统特朗普提名的食品药品监督管理局(FDA)局长人选海蒂·奥弗顿博士的提名。
此前计划于周三就奥弗顿的提名举行投票的参议院卫生、教育、劳工与养老金委员会(HELP委员会),将取消该投票安排。
Axios新闻网率先报道了奥弗顿被撤回提名的消息。
CBS新闻此前曾报道,奥弗顿一直难以争取到参议院共和党议员的支持。部分议员及白宫盟友对奥弗顿持怀疑态度,部分原因在于她就FDA批准的堕胎药物米非司酮所作的证词,以及她推行特朗普总统的支持电子烟政策的举措。
即将卸任的参议院HELP委员会主席、路易斯安那州共和党参议员比尔·卡西迪周二晚表示,问题并非奥弗顿缺乏获得确认所需的票数,而是“白宫放弃了可行的确认路径”。
卡西迪在一份声明中指出:“反堕胎派参议员曾寻求从政府方面获得关于其对生命议题承诺的最终保障”,但特朗普政府最终选择撤回了奥弗顿的提名。
“我认为她本会获得足够票数,从委员会通过提名并经参议院全体投票通过。我与她的交谈让我确信,她会遵循科学原则,抵制那些危及美国民众健康的决策,”他表示。
两名知情人士透露,白宫于周二晚间告知了撤回奥弗顿提名的决定。当时,共和党议员正在开展党团工作,以争取足够票数推动奥弗顿的提名获得通过。
奥弗顿是一名医生,曾担任白宫国内政策工作人员,特朗普总统于今年夏季提名她担任FDA局长。该机构监管着约占美国消费者支出20%的产品,自2026年5月马蒂·马卡里博士被迫离职后,一直没有获得参议院确认的正式局长。
奥弗顿被认为与本月早些时候离任的前白宫办公厅主任苏西·威尔士关系密切。
一名消息人士周二早些时候告诉CBS新闻,在决定撤回奥弗顿提名之前,白宫已开始与其他可能担任FDA局长的候选人接触,其中包括一些可以以代理身份任职、因此无需经过参议院确认的人选。该机构目前由代理局长凯尔·迪亚曼塔斯主持工作。
两名消息人士表示,堪萨斯州的共和党籍医生参议员罗杰·马歇尔正竞争FDA局长一职。但他在本月早些时候的连任选举中败给了民主党人亚当·汉密尔顿。
任何需经参议院确认的FDA局长人选,都必须在1月参议院由民主党掌控前的短暂窗口期内获得确认。
卡西迪周二告诉CBS新闻,“鉴于剩余时间有限,确认一名正式的FDA局长的任务将落到参议院民主党人身上。”
在周日接受《玛格丽特·布伦南主持的面对全国》节目采访时,卡西迪表示担忧,代理FDA局长的独立性会比经参议院确认的正式局长更弱。
“问题在于,我们希望看到一系列短期任职的管理者,他们可能会受到部长的更多影响,还是希望有这样一个人选——虽然在某些人看来未必是完美的候选人,但至少是正式任命的,能够建立起一定的独立性?”他说道。
White House drops Heidi Overton’s nomination for FDA commissioner
November 17, 2026 / 10:30 PM EST / CBS News
The White House has dropped the nomination of Dr. Heidi Overton, President Trump’s pick for Food and Drug Administration commissioner, according to a senior administration official and other people familiar with the decision.
The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on Overton’s nomination Wednesday.
Axios was first to report that Overton was dropped.
Overton had struggled to shore up support among Senate Republicans, CBS News had previously reported. Some lawmakers and administration allies had expressed skepticism of Overton, partly due to her testimony regarding the FDA-approved abortion drug mifepristone and her execution of Mr. Trump’s pro-vape policies.
Republican Sen. Bill Cassidy of Louisiana, the outgoing chair of the Senate HELP Committee, argued late Tuesday the issue was not that Overton lacked the votes to get confirmed. He said the “White House abandoned a viable confirmation path.”
Cassidy wrote in a statement that “pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues,” but the Trump administration withdrew Overton instead.
“I believe she would have had the votes to pass out of committee and pass the full Senate. My conversations with her convinced me she would follow the science and push back against decisions that put Americans’ health at risk,” he said.
Two sources familiar with the matter said the White House shared its decision to withdraw Overton’s nomination Tuesday evening. At the time, whip efforts were still underway to garner enough Republican votes to advance Overton.
Mr. Trump nominated Overton — a physician and White House domestic policy staffer — to the FDA role over the summer. The agency, which regulates products that account for about 20% of U.S. consumer spending, has not had a Senate-confirmed leader since Dr. Marty Makary was forced out in May.
Overton was seen as close to former White House chief of staff Susie Wiles, who departed her roleearlier this month.
Prior to the decision to withdraw Overton, the White House had begun talking to other potential candidates for FDA chief, including some who could serve in an acting capacity and thus forgo Senate confirmation, a source told CBS News earlier Tuesday. The agency is currently run by acting Commissioner Kyle Diamantas.
Two sources indicated Sen. Roger Marshall of Kansas, a doctor, is making a play for the FDA post. He lost his reelection bid to Democrat Adam Hamilton earlier this month.
Any Senate-confirmed FDA commissioner would need to be confirmed during a narrow window before Democrats take control of the chamber in January.
Cassidy told CBS News on Tuesday that “with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”
In an interview with “Face the Nation with Margaret Brennan” on Sunday, Cassidy expressed concern that an acting FDA administer would have less independence than a Senate-confirmed leader.
“The question is, do we want a series of short-term administrators who probably will have more influence from the secretary, as opposed to someone who may be not, you know, the perfect candidate in somebody’s mind, but at least would be a permanent one and have the ability to establish some independence?” he said.
发表回复